SABR (Stereotactic ablative radiotherapy) is one of the standard treatment options besides
surgical resection for limited lung metastases (oligometastases) from colorectal cancer. High
efficacy in terms of local control of metastatic lesions treated has been shown.
Nevertheless, the precise effect of SABR upon progression-free- and overall survival in these
patients is unknown. To further evaluate and develop local treatment options in metastatic
disease, more information is necessary regarding the impact upon - and the pattern of -
disease progression of local treatment options such as SABR.
To determine the effect upon progression free survival and upon tumorload relative to
baseline, both at one year after randomisation of immediate SABR versus delayed SABR (a
scan-and-personalise policy). Secondarily, patterns of progression, patient-reported symptoms
and quality of life will be monitored.